Novocure (NASDAQ: NVCR) is a pioneering oncology company that is dedicated to extending survival in some of the most aggressive forms of cancer. They have developed a novel therapy called Tumor Treating Fields (TTFields), which is aimed at solid tumors. Novocure aims to redefine living with cancer by developing and commercializing this innovative therapy.

With their headquarters in Haifa, Israel, Novocure has grown into a global oncology company since its founding in 2000. Their leadership team consists of experienced professionals from the oncology, biotechnology, and medical device industries. Novocure is committed to corporate social responsibility and supports independent organizations that share their goals of advancing medical care and improving patient outcomes.

The effectiveness of Tumor Treating Fields has been extensively researched, with ongoing or completed clinical trials for various cancers including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. To stay updated on the latest news and information from Novocure, you can follow them on LinkedIn and Twitter